Liraglutide vs Semaglutide
A once-daily GLP-1 receptor agonist; an earlier acylated analog. A long-acting GLP-1 receptor agonist engineered for once-weekly dosing. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Liraglutide | Semaglutide | |
|---|---|---|
| Also known as | Victoza, Saxenda | Ozempic, Wegovy, Rybelsus |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 receptor agonist (acylated, 31 aa) | GLP-1 receptor agonist (acylated peptide, 31 aa) |
| Receptor | GLP-1 receptor (GLP-1R) | GLP-1 receptor (GLP-1R) |
| Molecular weight | ~3,751.2 Da | ~4,113.6 Da |
| Half-life | ||
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Liraglutide and Semaglutide?
- Liraglutide is an engineered analog based on Glucagon-like peptide-1; Semaglutide is an engineered analog based on Glucagon-like peptide-1. Liraglutide signals at GLP-1 receptor (GLP-1R); Semaglutide signals at GLP-1 receptor (GLP-1R).
- How do the half-lives of Liraglutide and Semaglutide compare?
- The reported circulating half-life of Liraglutide is ~13 h; Semaglutide is ~7 days (~165 h). These are reference values for the native or representative form — educational only, not dosing advice.
- Is Liraglutide the same as Victoza?
- Victoza, Saxenda are brand names of Liraglutide. This comparison describes the molecules, not branded products.
Prefer the other order? Semaglutide vs Liraglutide. Or open the interactive comparison tool to add more molecules.